Chinedu C Ude, Shiv Shah, Kenneth S Ogueri, Lakshmi S Nair, Cato T Laurencin
{"title":"膝关节再生工程中骨关节炎基质血管组分的研究。","authors":"Chinedu C Ude, Shiv Shah, Kenneth S Ogueri, Lakshmi S Nair, Cato T Laurencin","doi":"10.1007/s40883-021-00226-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The knee joint is prone to osteoarthritis (OA) due to its anatomical position, and several reports have implicated the imbalance between catabolic and anabolic processes within the joint as the main culprit, thus leading to investigations towards attenuation of these inflammatory signals for OA treatment. In this review, we have explored clinical evidence supporting the use of stromal vascular fraction (SVF), known for its anti-inflammatory characteristics for the treatment of OA.</p><p><strong>Methods: </strong>Searches were made on PubMed, PMC, and Google Scholar with the keywords \"adipose fraction knee regeneration, and stromal vascular fraction knee regeneration, and limiting searches within 2017-2020.</p><p><strong>Results: </strong>Frequently found interventions include cultured adipose-derived stem cells (ADSCs), SVF, and the micronized/microfragmented adipose tissue-stromal vascular fraction (MAT-SVF). Clinical data reported that joints treated with SVF provided a better quality of life to patients. Currently, MAT-SVF obtained and administered at the point of care is approved by the Food and Drug Administration (FDA), but more studies including manufacturing validation, safety, and proof of pharmacological activity are needed for SVF. The mechanism of action of MAT-SVF is also not fully understood. However, the current hypothesis indicates a direct adherence and integration with the degenerative host tissue, and/or trophic effects resulting from the secretome of constituent cells.</p><p><strong>Conclusion: </strong>Our review of the literature on stromal vascular fraction and related therapy use has found evidence of efficacy in results. More research and clinical patient follow-up are needed to determine the proper place of these therapies in the treatment of osteoarthritis of the knee.</p><p><strong>Lay summary: </strong>Reports have implicated the increased inflammatory proteins within the joints as the main cause of osteoarthritis (OA). This has attracted interest towards addressing these inflammatory proteins as a way of treatment for OA. The concentrated cell-packed portion of the adipose product stromal vascular fraction (SVF) from liposuction or other methods possesses anti-inflammatory effects and has been acclaimed to heal OA. Thus, we searched for clinical evidence supporting their use, for OA treatment through examining the literature. Data from various hospitals support that joints treated with SVF provided a better quality of life to patients. Currently, there is at least one version of these products that are obtained and given back to patients during a single clinic visit, approved by the FDA.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40883-021-00226-x","citationCount":"11","resultStr":"{\"title\":\"Stromal Vascular Fraction for Osteoarthritis of the Knee Regenerative Engineering.\",\"authors\":\"Chinedu C Ude, Shiv Shah, Kenneth S Ogueri, Lakshmi S Nair, Cato T Laurencin\",\"doi\":\"10.1007/s40883-021-00226-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The knee joint is prone to osteoarthritis (OA) due to its anatomical position, and several reports have implicated the imbalance between catabolic and anabolic processes within the joint as the main culprit, thus leading to investigations towards attenuation of these inflammatory signals for OA treatment. In this review, we have explored clinical evidence supporting the use of stromal vascular fraction (SVF), known for its anti-inflammatory characteristics for the treatment of OA.</p><p><strong>Methods: </strong>Searches were made on PubMed, PMC, and Google Scholar with the keywords \\\"adipose fraction knee regeneration, and stromal vascular fraction knee regeneration, and limiting searches within 2017-2020.</p><p><strong>Results: </strong>Frequently found interventions include cultured adipose-derived stem cells (ADSCs), SVF, and the micronized/microfragmented adipose tissue-stromal vascular fraction (MAT-SVF). Clinical data reported that joints treated with SVF provided a better quality of life to patients. Currently, MAT-SVF obtained and administered at the point of care is approved by the Food and Drug Administration (FDA), but more studies including manufacturing validation, safety, and proof of pharmacological activity are needed for SVF. The mechanism of action of MAT-SVF is also not fully understood. However, the current hypothesis indicates a direct adherence and integration with the degenerative host tissue, and/or trophic effects resulting from the secretome of constituent cells.</p><p><strong>Conclusion: </strong>Our review of the literature on stromal vascular fraction and related therapy use has found evidence of efficacy in results. More research and clinical patient follow-up are needed to determine the proper place of these therapies in the treatment of osteoarthritis of the knee.</p><p><strong>Lay summary: </strong>Reports have implicated the increased inflammatory proteins within the joints as the main cause of osteoarthritis (OA). This has attracted interest towards addressing these inflammatory proteins as a way of treatment for OA. The concentrated cell-packed portion of the adipose product stromal vascular fraction (SVF) from liposuction or other methods possesses anti-inflammatory effects and has been acclaimed to heal OA. Thus, we searched for clinical evidence supporting their use, for OA treatment through examining the literature. Data from various hospitals support that joints treated with SVF provided a better quality of life to patients. Currently, there is at least one version of these products that are obtained and given back to patients during a single clinic visit, approved by the FDA.</p>\",\"PeriodicalId\":20936,\"journal\":{\"name\":\"Regenerative Engineering and Translational Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s40883-021-00226-x\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regenerative Engineering and Translational Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40883-021-00226-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/8/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative Engineering and Translational Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40883-021-00226-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Stromal Vascular Fraction for Osteoarthritis of the Knee Regenerative Engineering.
Purpose: The knee joint is prone to osteoarthritis (OA) due to its anatomical position, and several reports have implicated the imbalance between catabolic and anabolic processes within the joint as the main culprit, thus leading to investigations towards attenuation of these inflammatory signals for OA treatment. In this review, we have explored clinical evidence supporting the use of stromal vascular fraction (SVF), known for its anti-inflammatory characteristics for the treatment of OA.
Methods: Searches were made on PubMed, PMC, and Google Scholar with the keywords "adipose fraction knee regeneration, and stromal vascular fraction knee regeneration, and limiting searches within 2017-2020.
Results: Frequently found interventions include cultured adipose-derived stem cells (ADSCs), SVF, and the micronized/microfragmented adipose tissue-stromal vascular fraction (MAT-SVF). Clinical data reported that joints treated with SVF provided a better quality of life to patients. Currently, MAT-SVF obtained and administered at the point of care is approved by the Food and Drug Administration (FDA), but more studies including manufacturing validation, safety, and proof of pharmacological activity are needed for SVF. The mechanism of action of MAT-SVF is also not fully understood. However, the current hypothesis indicates a direct adherence and integration with the degenerative host tissue, and/or trophic effects resulting from the secretome of constituent cells.
Conclusion: Our review of the literature on stromal vascular fraction and related therapy use has found evidence of efficacy in results. More research and clinical patient follow-up are needed to determine the proper place of these therapies in the treatment of osteoarthritis of the knee.
Lay summary: Reports have implicated the increased inflammatory proteins within the joints as the main cause of osteoarthritis (OA). This has attracted interest towards addressing these inflammatory proteins as a way of treatment for OA. The concentrated cell-packed portion of the adipose product stromal vascular fraction (SVF) from liposuction or other methods possesses anti-inflammatory effects and has been acclaimed to heal OA. Thus, we searched for clinical evidence supporting their use, for OA treatment through examining the literature. Data from various hospitals support that joints treated with SVF provided a better quality of life to patients. Currently, there is at least one version of these products that are obtained and given back to patients during a single clinic visit, approved by the FDA.
期刊介绍:
Regenerative Engineering is an international journal covering convergence of the disciplines of tissue engineering, advanced materials science, stem cell research, the physical sciences, and areas of developmental biology. This convergence brings exciting opportunities to translate bench-top research into bedside methods, allowing the possibility of moving beyond maintaining or repairing tissues to regenerating them. The journal encourages both top-down engineering approaches and bottom-up strategies integrating materials science with stem cell research and developmental biology. Convergence papers on instructive biomaterials, stimuli-responsive biomaterials, micro- and nano-patterning for regenerative engineering, elastomeric biomaterials, hydrogels for tissue engineering, and rapid prototyping and bioprinting approaches are particularly welcome.
The journal provides a premier, single-blind peer-reviewed forum for the publication of original papers, authoritative reviews, rapid communications, news and views, and opinion papers addressing the most important issues and efforts toward successfully regenerating complex human tissues and organs. All research articles feature a lay abstract highlighting the relevance and future impact for patients, government and other health officials, and members of the general public. Bridging the gap between the lab and the clinic, the journal also serves as a dedicated platform for showcasing translational research that brings basic scientific research and discoveries into clinical methods and therapies, contributing to the improvement of human health care.
Topics covered in Regenerative Engineering and Translational Medicine include:
Advanced materials science for regenerative and biomedical applicationsStem cells for tissue regenerationDrug delivery for tissue regenerationNanomaterials and nanobiotechnology for tissue regenerationStudies combining tissue engineering/regeneration with developmental biologyConvergence research in pre-clinical and clinical phases